Gapping up
In reaction to strong earnings/guidance:
- N/A.
M&A news:
- ALDR +80.1% (to be acquired by H. Lundbeck A/S (HLUYY) for $18.00/share in cash + CVR)
- SEMG +63.4% (to be acquired by Energy Transfer LP (ET) for $17/share in cash and stock)
Select metals/mining stocks trading higher:
- GFI +3.8%, HMY +3.7%, SBGL +3.3%, GDX +2.6%, SLV +2.4%, AU +2.3%, HL +2.2%, AUY +1.9%, NEM +1.8%, GOLD +0.5%
Select oil/gas related names showing strength:
- YUMA +59%, DNR +27.9%, WLL +22.1%, CHK +21.3%, VAL +16.4%, AR +13.6%, NBR +13%, RIG +12.9%, DVN +12.7%, RRC +12.3%, BTE +12.2%, MRO +12%, SWN +10.3%, PTEN +10.1%, APA +9.7%, ECA +9.5%, CXO +9.2%, PXD +9.1%, NBL +9%, MDR +8.8%, CNQ +8.1%, HES +8%, COP +7.6%, SLB +7.6%, NOV +7.5%, HAL +7.1%, OXY +6.8%, BP +4.7%, XOM +3.9%, CVX +3.5%, RDS.A +2.7%, ENB +2.6%, HFC +1.9%, VLO +1.8%
Other news:
- AIMT +14.5% (confirms positive FDA advisory committee vote)
- ARWR +3.2% (presents initial top-line clinical data and preclinical data on RNAi candidates ARO-APOC3 and ARO-ANG3)
- AZN +1% (FDA grants Fast Track designation for Farxiga in heart failure)
Analyst comments:
- SM +15% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- ARQL +6% (initiated with a Buy at H.C. Wainwright; tgt $13 -- Aiming for success with precision drugs in both oncology and rare overgrowth disorder markets)
- CARS +2.8% (upgraded to Buy from Hold at Craig Hallum)
- GBX +2% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- RTN +1.4% (upgraded to Overweight from Neutral at JP Morgan)
- LYFT +0.9% (upgraded to Buy from Hold at HSBC Securities)
- LOW +0.9% (upgraded to Outperform from Neutral at Wedbush)
- UBER +0.8% (upgraded to Buy from Hold at HSBC Securities)